Approval of Pembrolizumab Enfortumab Therapy: I...

By João L. Carapinha

April 8, 2025

The German Federal Joint Committee (G-BA) has approved a new indication for Pembrolizumab Enfortumab therapy in combination with Enfortumab Vedotin as a first-line treatment for adult patients with unresectable or metastatic urothelial carcinoma. ...

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.